ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 269,60
-0,05%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Processa Pharmaceuticals Inc (PCSA)

  7. Processa Pharmaceuticals Inc (PCSA) Actualités

PCSA

Processa Pharmaceuticals (PCSA)

Processa Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PCSA
DateHeureSourceTitreSymboleSociété
29/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PCSAProcessa Pharmaceuticals Inc
28/05/202422h49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
21/05/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCSAProcessa Pharmaceuticals Inc
21/05/202422h10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PCSAProcessa Pharmaceuticals Inc
10/05/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
06/05/202414h00GlobeNewswire Inc.Processa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/04/202414h00GlobeNewswire Inc.Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical ResearchNASDAQ:PCSAProcessa Pharmaceuticals Inc
11/04/202414h00GlobeNewswire Inc.Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b TrialNASDAQ:PCSAProcessa Pharmaceuticals Inc
28/03/202413h15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/03/202413h15GlobeNewswire Inc.Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual MeetingNASDAQ:PCSAProcessa Pharmaceuticals Inc
21/02/202414h15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
14/02/202419h00GlobeNewswire Inc.Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
06/02/202414h30GlobeNewswire Inc.Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleNASDAQ:PCSAProcessa Pharmaceuticals Inc
02/02/202400h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCSAProcessa Pharmaceuticals Inc
01/02/202422h22GlobeNewswire Inc.Processa Pharmaceuticals Announces Closing of $7.0 Million Public OfferingNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/01/202422h15Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:PCSAProcessa Pharmaceuticals Inc
26/01/202415h04GlobeNewswire Inc.Processa Pharmaceuticals Announces Pricing of $7.0 Million Public OfferingNASDAQ:PCSAProcessa Pharmaceuticals Inc
25/01/202414h30GlobeNewswire Inc.Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 DosesNASDAQ:PCSAProcessa Pharmaceuticals Inc
19/01/202413h45GlobeNewswire Inc.Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast CancerNASDAQ:PCSAProcessa Pharmaceuticals Inc
18/01/202413h45GlobeNewswire Inc.Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock SplitNASDAQ:PCSAProcessa Pharmaceuticals Inc
02/01/202423h06GlobeNewswire Inc.Processa Pharmaceuticals to Present at the Biotech Showcase 2024NASDAQ:PCSAProcessa Pharmaceuticals Inc
29/12/202314h55Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PCSAProcessa Pharmaceuticals Inc
19/12/202315h00GlobeNewswire Inc.Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/12/202315h00GlobeNewswire Inc.Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation CapecitabineNASDAQ:PCSAProcessa Pharmaceuticals Inc
30/11/202314h15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the MedInvest Oncology Investor ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
29/11/202314h15GlobeNewswire Inc.Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and OutlookNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/11/202319h40GlobeNewswire Inc.Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil ThompsonNASDAQ:PCSAProcessa Pharmaceuticals Inc
09/11/202314h15GlobeNewswire Inc.Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 AmericasNASDAQ:PCSAProcessa Pharmaceuticals Inc
01/11/202313h15GlobeNewswire Inc.Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion LeadersNASDAQ:PCSAProcessa Pharmaceuticals Inc
13/10/202319h08GlobeNewswire Inc.Processa Pharmaceuticals to Present at the ThinkEquity ConferenceNASDAQ:PCSAProcessa Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PCSA

Dernières Valeurs Consultées

TSX
MEME.B
Manulife Multifactor Eme...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés